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THE EPIDEMIOLOGICAL REVOLUTION OF THE 20th CENTURY
S. De Flora, A. Quaglia, C. Bennicelli & M. Vercelli, FASEB J. 19, 892–897, 2005
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1. Inhibition of mutation and cancer initiation in the extracellular environment or in 
nontarget cells
1.1. Inhibition of uptake of mutagens/carcinogens
1.1.1. Inhibition of penetration
1.1.2. Removal from the organism
1.2. Inhibition of the endogenous formation of mutagens
and carcinogens
1.2.1. Inhibition of the nitrosation reaction
1.2.2. Modification of the intestinal microbial flora
1.3. Complexation, dilution and/or deactivation of 
mutagens/carcinogens outside cells
1.3.1. By physical or mechanical means
1.3.2. By chemical reaction
1.3.3. By enzyme–catalyzed reaction
1.4. Favoring absorption of protective agents
1.5. Stimulation of trapping and detoxification in nontarget cells
 
2. Inhibition of mutation and cancer initiation in target cells
2.1. Modification of transmembrane transport
2.1.1. Inhibition of cellular uptake
2.1.2. Stimulation of extrusion outside cells
2.2. Modulation of metabolism
2.2.1. Inhibition of activation of promutagens/ procarcinogens by               
           Phase I enzymes
2.2.2. Induction of Phase I detoxification and Phase II 
           conjugation pathways, or acceleration of decomposition 
           of reactive metabolites
2.2.3. Stimulation of activation, coordinated with
           detoxification and blocking of reactive metabolites
2.3. Blocking or competition
2.3.1. Trapping of electrophiles by either chemical reaction or   
           enzyme–catalyzed conjugation
2.3.2. Antioxidant activity and scavenging of reactive species
2.3.3. Protection of DNA nucleophilic sites
2.4. Inhibition of cell replication
2.5. Maintenance of DNA structure and modulation of DNA metabolism and repair
2.5.1. Increase of fidelity of DNA replication and repair   
2.5.2. Stimulation of repair and/or reversion of DNA damage
2.5.3. Inhibition of error-prone repair pathways
2.5.4. Correction of hypomethylation
2.5.5. Inhibition of histone deacetylation            
2.5.6. Blocking of telomerases or inhibition of their activity
2.6. Control of gene expression
                    2.6.1. Targeted inactivation of oncogenes
             2.6.2. Inhibitionofoncogene expression
2.6.3. Inhibition of oncogene sequences or activity
    2.6.3.1. Inhibition of translation targeted to oncogene mRNA
    2.6.3.2. Inhibition of transcription of specific DNA sequences
    2.6.3.3. Blocking of target genes
    2.6.2.4. Farnesyltransferase inhibition
2.6.4. Neutralization or post–translational modification of oncogene products
2.6.5. Replacement of deleted tumor suppressor genes
2.6.6. Mimicking the DNA binding of tumor suppressor genes by antiidiotypic antibodies
2.6.7. Killing of cells lacking tumor suppressor genes
3.  Inhibition of tumor promotion
3.1. Inhibition of genotoxic effects (see 1 and 2)
3.2. Antioxidant activity and scavenging of free radicals
3.3. Antiinflammatory activity
3.3.1.   Cyclooxygenase inhibition
3.3.2.   Lipooxygenase inhibition
3.3.3.   Inhibition of inducible nitric oxide synthase
3.3.4.   Leukotriene receptor antagonism
3.4. Inhibition of proteases
3.5. Inhibition of cell proliferation
3.5.1.   Inhibition of ornithine decarboxylase
3.5.2.   Promoting proteasomal degradation of cyclins
3.5.3.   Interference with multiple signaling pathways
3.6. Induction of cell differentiation
3.7. Modulation of cell apoptosis
3.8. Signal transduction modulation
3.9. Protection of intercellular communications
4.  Inhibition of tumor progression
4.1. Inhibition of genotoxic effects (see 1 and 2)
4.2. Antioxidant activity and scavenging of free radicals
4.3. Inhibition of proteases
4.4. Signal transduction modulation
4.5. Effects on the hormonal status
4.5.1.   Selective estrogen receptor modulation
4.5.2.   Aromatase inhibition
4.5.3.   Selective blocking of prostaglandin E2 receptors
4.5.4.   Decrease in ovarian hormones by dietary isoflavones
4.5.5.   Inhibiting the pituitary secretion of luteinizing hormone
4.5.6.   Preventing conversion of testosterone into
 dehydrotestosterone by 5a–reductase
4.5.7.   Selective androgen receptor antagonism
4.6. Effects on the immune system
4.7. Inhibition of angiogenesis
4.8. Antineoplastic activity by either mechanical, physical, chemical, or biological means
5. Inhibition of invasion and metastasis
5.1. Antioxidant activity and scavenging of free radicals
5.2. Signal transduction modulation
5.3. Inhibition of cell proliferation (see 3.4)
5.4. Modulation of cell apoptosis
5.5. Induction of cell differentiation
5.6. Inhibition of angiogenesis
5.7. Effect on cell-adhesion molecules
5.8. Inhibition of proteases involved in basement membrane degradation and 
       modulation of the interaction with the extracellular matrix
5.9. Activation of antimetastasis genes
MECHANISMS OF CANCER CHEMOPREVENTIVE AGENTS
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2.5. Maintenance of DNA structure and modulation of DNA metabolism and repair
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3.  Inhibition of tumor promotion
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4.  Inhibition of tumor progression
4.1. Inhibition of genotoxic effects (see 1 and 2)
4.2. Antioxidant activity and scavenging of free radicals
4.3. Inhibition of proteases
4.4. Signal transduction modulation
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5. Inhibition of invasion and metastasis
5.1. Antioxidant activity and scavenging of free radicals
5.2. Signal transduction modulation
5.3. Inhibition of cell proliferation (see 3.4)
5.4. Modulation of cell apoptosis
5.5. Induction of cell differentiation
5.6. Inhibition of angiogenesis
5.7. Effect on cell-adhesion molecules
5.8. Inhibition of proteases involved in basement membrane degradation 
and modulation of the interaction with the extracellular matrix
5.9. Activation of antimetastasis genes
MECHANISMS OF CANCER CHEMOPREVENTIVE AGENTS




























































DNA damage and repair
Cytogenetic effects
Activation of oncogenes
Deletion/mutation of oncosuppressor genes





































































DNA damage and repair
Cytogenetic effects
Activation of oncogenes
Deletion/mutation of oncosuppressor genes





















































































Cancer / Chemicals and  









































































     COPD
(A. Izzotti et al., FASEB J. 17, 1127-29, 2003)





















































































































































































   Eye diseases
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GENOMIC CHANGES IN MOUSE LUNG AT BIRTH
A. Izzotti et al., Mutat. Res. (Rev. Genetic Toxicol.), 544, 441-449, 2003
DNA adducts Expression of 746 genes8-oxo-dGuo
Newborn mice / fetuses
5.01.9














































MICE EXPOSED TO SMOKE AFTER BIRTH
61.1 %










































SHAM NAC OPZ OPZ
+ NAC
5,6-BF PEITC I3C PEITC
+ I3C












































































EFFECT OF CIGARETTE SMOKE (ECS) AND CHEMOPREVENTIVE 
AGENTS ON miRNA EXPRESSION IN RAT LUNG






































































S. De Flora & F. D’Agostini, Nature 356, 569, 1992
WITH COVERWITHOUT COVER
SKIN CARCINOGENICITY OF HALOGEN LAMPS 



































MODULATION OF LIGHT-INDUCED SKIN TUMORS BY
N–ACETYLCYSTEINE (NAC) AND ASCORBIC ACID (ASA)
F. D’Agostini et al., Carcinogenesis 26, 657–664, 2005




































































THE PREVENTION OF INFECTION–ASSOCIATED CANCERS














α HPV type 16
α HPV types 18, 31, 33, 35,
39, 45, 51, 52, 56, 58, 59




Cancers at several sites
Cervical cancer
Cervical cancer
α HPV types 26, 30, 34, 53,
66, 67, 69, 70, 73, 82, 85, 97 2B Cervical cancer
(S. De Flora and P. Bonanni, 2010)
β  HPV type 5 and 8 2B Skin cancer
α HPV type 6 and 11 3 None
Pathogen Main asociated cancerIARC
Group
Other β and γ  HPV types 3 None
Polyomaviruses
JCV NA CNS tumors and colorectal
cancer?
MCV NA Skin cancer (Merkel cell
carcinoma)
SV40 NA Malignant mesothelioma ?
Herpesviruses



















cervical cancer, anus cancer,
conjunctive cancer
Helicobacter pylori 1 Gastric cancer, MALT
HIV-II 2B Kaposi’s sarcoma, non-Hodgkin’s
lymphoma
HERV-K NA Human breast cancer
Schistosomes
S. haematubium 1 Urinary bladder cancer
S. japonicum 2B Colorectal and liver cancers
S. mansoni 3 None
Liver flukes
Opistorchis viverrini 1 Cholangiocarcinoma
Opistorchis felineus 3 None
Chlonorchis sinensis 1 Cholangiocarcinoma
Infectious agents cause 17% of all cancers 
worldwide, 26% in developing world, 
8% in developed world 
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4.9% of all cancers
85.5% of all HCCs
5.2% of all cancers
100% of cervix cancers
5.5% of all ancers
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S. De Flora et al, Cancer Res. 47, 4052–8, 1987; Carcinogenesis 10, 1099–1106, 1989































































































S. De Flora et al., FASEB J. 11: 1021-1031, 1997
The levels of  32P postlabelled DNA adducts in the aorta from
85 atherosclerotic patients were significantly correlated with: 
-Age of patients
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MODULATION OF DNA ADDUCTS BY DIETARY
AGENTS IN THE AORTA OF SMOKE-EXPOSED RATS
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MODULATION OF DNA ADDUCTS BY DIETARY
AGENTS IN THE HEART OF SMOKE-EXPOSED RATS







ECS + NAC + OPZ









































EARLY INTERVENTION(Cancer patients in preclinical or early stage)
PREVENTION OF PROGRESSION
(Individuals affected by precancerous lesions)
TARGETED CHEMOPREVENTION
(High risk individuals) 
PUBLIC HEALTH INTERVENTION











































PHASE II CHEMOPREVENTION TRIAL
WITH NAC IN DUTCH SMOKERS
















6.0 ± 0.7 4.8 ± 0.5 1.2 ± 0.3
5.9 ± 0.7 3.2 ± 0.8 1.0 ± 0.2
6.0 ± 0.9 4.9 ± 0.7 1.3 ± 0.3
4.3 ± 0.8 1.8 ± 0.3 0.9 ± 0.3
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